In this open-label trial, a higher proportion of asymptomatic follicular lymphoma patients assigned to rituximab required no further treatment at nearly 15 years compared with those assigned to ...

A 1000 mg ×2 induction regimen followed by maintenance every 6–12 months was associated with near-elimination of relapse ...

The BRUIN CLL-322 trial evaluated the safety and efficacy of pirtobrutinib plus venetoclax and rituximab in previously treated CLL/SLL patients.

Anti-CD20 B cell-depleting agents such as rituximab may offer a promising initial disease-modifying treatment (DMT) for relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple ...

Rituximab is linked to a lower 5-year risk for new cancer than mycophenolate mofetil or azathioprine in patients with ...

Although the anti-CD20 B-cell depleting biological agent rituximab has been shown in small series and single-arm studies to effectively treat frequently relapsing nephrotic syndrome (FRNS) and steroid ...

Significantly more patients with moderate-to-severe pemphigus sustained their complete remission with rituximab (Rituxan) than with mycophenolate mofetil (MMF), a randomized trial showed. At 1 year, ...

Please provide your email address to receive an email when new articles are posted on . ATLANTA — Treatment with repeat doses of rituximab is superior to daily azathioprine for preventing relapse ...

Chronic lymphocytic leukemia (CLL) is known to be associated with various autoimmune phenomena. Autoimmune hemolytic anemia (AIHA) is the commonest manifestation of such disorders in CLL. 1,2 ...

The objective of this randomized trial was to assess the efficacy and safety of rituximab as in vivo purging before transplantation and as maintenance treatment immediately after high-dose ...

Rituximab no better than glucocorticoids alone for inducing remission in patients with eosinophilic granulomatosis with polyangiitis. HealthDay News — For patients with eosinophilic granulomatosis ...

The appraisal committee reviewed the data available on the clinical and cost effectiveness of rituximab, having considered evidence on the nature of anti-neutrophil cytoplasmic antibody ...